prikaz prve stranice dokumenta The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
  Preuzmi
PDF 459.32 KB
Znanstveni rad - Izvorni znanstveni rad
The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
Pediatric Rheumatology, 12 (2014), 1; 50. https://doi.org/10.1186/1546-0096-12-50
Bobek, Dubravka; Grčević, Danka; Kovačić, Nataša; Lukić, Ivan Krešimir; Jelušić, Marija

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Bobek, D., Grčević, D., Kovačić, N., Lukić, I. K. i Jelušić, M. (2014). The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatric Rheumatology, 12. (1), 50. doi: 10.1186/1546-0096-12-50

Bobek, Dubravka, et al. "The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus." Pediatric Rheumatology, vol. 12, br. 1, 2014, str. 50. https://doi.org/10.1186/1546-0096-12-50

Bobek, Dubravka, Danka Grčević, Nataša Kovačić, Ivan Krešimir Lukić i Marija Jelušić. "The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus." Pediatric Rheumatology 12, br. 1 (2014): 50. https://doi.org/10.1186/1546-0096-12-50

Bobek, D., et al. (2014) 'The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus', Pediatric Rheumatology, 12(1), str. 50. doi: 10.1186/1546-0096-12-50

Bobek D, Grčević D, Kovačić N, Lukić IK, Jelušić M. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatric Rheumatology [Internet]. 03.12.2014. [pristupljeno 23.11.2024.];12(1):50. doi: 10.1186/1546-0096-12-50

D. Bobek, D. Grčević, N. Kovačić, I. K. Lukić i M. Jelušić, "The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus", Pediatric Rheumatology, vol. 12, br. 1, str. 50, Prosinac 2014. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:974842. [Citirano: 23.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:974842
Podaci o radu
Naslov (engleski)The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
AutorDubravka Bobek
AutorDanka Grčević
AutorNataša Kovačić
AutorIvan Krešimir Lukić
AutorMarija Jelušić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
BACKGROUND: The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers. ----- METHODS: Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE and 27 healthy controls) were determined by ELISA. ----- RESULTS: The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1 and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to hepatosplenomegaly or serositis in systemic onset JIA. ----- CONCLUSION: The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPediatric Rheumatology
Brojčani podacivol. 12, br. 1, str. 50
p-ISSN1546-0096
DOIhttps://doi.org/10.1186/1546-0096-12-50
URN:NBNurn:nbn:hr:105:974842
Datum objave publikacije2014-12-03
URL dokumentahttps://doi.org/10.1186/1546-0096-12-50
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 20:16:02